{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132710","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.063569+00:00","generated_at":"2026-05-20T03:14:04.703179+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xilio reports 26% ORR for vilastobart+atezo in MSS CRC without liver mets; plans to partner program","bullets":["26% ORR (7 PRs, 6 confirmed) in 27 MSS CRC patients without liver metastases; responses ongoing up to 37 weeks.","Differentiated safety: only 7% colitis (3/44), low discontinuation (5%); combination well-tolerated.","Patient with liver metastasis from Phase 1C on treatment >14 months; 150mg Q6W dose cleared and cohort enrolling.","Xilio seeking partnership for vilastobart to accelerate development; additional data expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132710","json":"https://secwatch.observer/filing/0001193125-25-132710.json","markdown":"https://secwatch.observer/filing/0001193125-25-132710.md","text":"https://secwatch.observer/filing/0001193125-25-132710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525132710/0001193125-25-132710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525132710/d91295d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:14:04.703179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}